Company: BIVIW
Filing Date: 2025-02-11
Form Type: 10-Q
Source: 0001520138-25-000056
Chunk: 5

Company: BIOVIE INC.
Filing Date: 2025-02-11
Form: 10-Q
Item: Part I, Item 2
Chunk 5
---
the reduction in force in December 2023, and a decrease in consultancy expense of approximately $1.0 million, resulting from declining
use of consultants as the clinical studies were completed in the prior fiscal year, a decrease in Chemistry, Manufacturing and Controls
(“CMC”) and new drug discovery totaling approximately $344,000, a reduction in the use of regulatory and other consultants
totaling approximately $186,000, and a decrease in related expenses of approximately $59,000 in travel, conferences and publications.

The table below summarizes the expenses incurred for
the three months ended December 31, 2024 and 2023 by study:

    Three Months Ended  
    Three Months Ended  
    Increase 

    December 31, 2024  
    December 31, 2023  
    (Decrease) 

    Current Studies 

    Sunrise PD Phase 2 
    $1,161,342  
    $-  
    $1,161,342 
  
    Long Covid Program 
    2,255,898  
    -  
    2,255,898 
  
    Investigator-Initiated studies 
    2,159  
    -  
    2,159 

    $3,419,399  
    $-  
    $3,419,399 

    Completed Studies 

    Ascites BIV201 Phase 2b 
    $48,562  
    $132,633  
    $(84,071)
  
    AD mild to moderate pivotal Phase 3 
    26,091  
    2,685,413  
    (2,659,322)
  
    PD Phase 2 
    -  
    308,705  
    (308,705)
  
    Investigator-Initiated studies 
    -  
    14,913  
    (14,913)
  
    Other studies in development/canceled 
    -  
    2,625  
    (2,625)

    $74,653  
    $3,144,289  
    $(3,069,636)

 24 

Selling, General and Administrative Expenses

Selling, general and administrative expenses were
approximately $2.5 million and $2.3 million for the three months ended December 31, 2024 and 2023, respectively. The net